Tyrosine kinase inhibitors are potent acute pulmonary vasodilators in rats

American Journal of Respiratory Cell and Molecular Biology

Volumn 45, Issue 4, 2011, Pages 804-808

  Abe, Kohtaro ^a,b   Toba, Michie ^a   Alzoubi, Abdallah ^a   Koubsky, Karel ^a   Ito, Masako ^a   Ota, Hiroki ^a   Gairhe, Salina ^a   Gerthoffer, William T ^a,b   Fagan, Karen A ^a   McMurtry, Ivan F ^a   Oka, Masahiko ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

Ca 2+ sensitization; Pulmonary hypertension; SU5416; Tyrosine kinase inhibitors; Vasodilation

Indexed keywords

15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; IMATINIB; MYOSIN LIGHT CHAIN PHOSPHATASE; NILOTINIB; NITRIC OXIDE SYNTHASE; PROTEIN TYROSINE KINASE INHIBITOR; SEROTONIN; SORAFENIB;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; HEART OUTPUT; MALE; NONHUMAN; PROTEIN PHOSPHORYLATION; PULMONARY ARTERY; PULMONARY HYPERTENSION; RAT; SYSTOLIC BLOOD PRESSURE; VASODILATATION; WESTERN BLOTTING;

ANIMALS; ANTIHYPERTENSIVE AGENTS; BENZENESULFONATES; BLOTTING, WESTERN; CALCIUM; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HYPERTENSION, PULMONARY; MALE; MYOSIN LIGHT CHAINS; MYOSIN-LIGHT-CHAIN PHOSPHATASE; PHOSPHORYLATION; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PULMONARY ARTERY; PYRIDINES; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; VASODILATION; VASODILATOR AGENTS; VENTRICULAR FUNCTION, LEFT; VENTRICULAR FUNCTION, RIGHT; VENTRICULAR PRESSURE;

RATTUS;

EID: 80052092055     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2010-0371OC     Document Type: Article

References (31)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004;351:1425-1436.
2. Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK,Wood R, et al. Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res 2002;8:935-942. (Pubitemid 34520420)
3. Dagher R, Cohen M, Williams G, Rothmann M, Gobburu J, Robbie G, Rahman A, Chen G, Staten A, Griebel D, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-3038. (Pubitemid 35155011)
4. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412-1413. (Pubitemid 41362714)
5. Klein M, Schermuly RT, Ellinghaus P, Milting H, Riedl B, Nikolova S, Pullamsetti SS, Weissmann N, Dony E, Savai R, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008;118:2081-2090.
6. Moreno-Vinasco L, Gomberg-Maitland M, Maitland ML, Desai AA, Singleton PA, Sammani S, Sam L, Liu Y, Husain AN, Lang RM, et al. Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension. Physiol Genomics 2008;33:278-291. (Pubitemid 351629535)
7. Schermuly RT, Dony E, Ghofrani HA, Pullamsetti S, Savai R, Roth M, Sydykov A, Lai YJ, Weissmann N, Seeger W, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811-2821. (Pubitemid 41434408)
8. Fernandez-Patron C. Therapeutic potential of the epidermal growth factor receptor transactivation in hypertension: a convergent signaling pathway of vascular tone, oxidative stress, and hypertrophic growth downstream of vasoactive G-protein-coupled receptors? Can J Physiol Pharmacol 2007;85:97-104. (Pubitemid 46996108)
9. Florian JA, Watts SW. Epidermal growth factor: a potent vasoconstrictor in experimental hypertension. Am J Physiol 1999;276:H976-H983. (Pubitemid 29157471)
10. Sauro MD, Thomas B. Tyrphostin attenuates platelet-derived growth factor-induced contraction in aortic smooth muscle through inhibition of protein tyrosine kinase(s). J Pharmacol Exp Ther 1993;267:1119-1125. (Pubitemid 24068674)
11. Berk BC, Alexander RW. Vasoactive effects of growth factors. Biochem Pharmacol 1989;38:219-225. (Pubitemid 19033330)
12. Oka M, Homma N, Taraseviciene-Stewart L, Morris KG, Kraskauskas D, Burns N, Voelkel NF, McMurtry IF. Rho kinase-mediated vasoconstriction is important in severe occlusive pulmonary arterial hypertension in rats. Circ Res 2007;100:923-929. (Pubitemid 46555698)
13. Taraseviciene-Stewart L, Kasahara Y, Alger L, Hirth P, Mc Mahon G, Waltenberger J, Voelkel NF, Tuder RM. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427-438. (Pubitemid 32141434)
14. Puetz S, Lubomirov LT, Pfitzer G. Regulation of smooth muscle contraction by small GTPases. Physiology (Bethesda) 2009;24:342-356.
15. Somlyo AP, Somlyo AV. Ca21 sensitivity of smooth muscle and nonmuscle myosin ii: modulated by g proteins, kinases, and myosin phosphatase. Physiol Rev 2003;83:1325-1358. (Pubitemid 37222274)
16. McMurtry IF, Abe K, Ota H, Fagan KA, Oka M. Rho kinase-mediated vasoconstriction in pulmonary hypertension. Adv Exp Med Biol 2010;661:299-308.
17. Oka M, Fagan KA, Jones PL, McMurtry IF. Therapeutic potential of RhoA/Rho kinase inhibitors in pulmonary hypertension. Br J Pharmacol 2008;155:444-454.
18. Oka M, Hasunuma K, Webb SA, Stelzner TJ, Rodman DM, McMurtry IF. EDRF suppresses an unidentified vasoconstrictor mechanism in hypertensive rat lungs. Am J Physiol 1993;264:L587-L597. (Pubitemid 23195779)
19. Tsai MH, Jiang MJ. Rho-kinase-mediated regulation of receptor-agonist- stimulated smooth muscle contraction. Pflugers Arch 2006;453:223-232. (Pubitemid 44630456)
20. Deininger M, Buchdunger E, Druker BJ. The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood 2005;105:2640-2653. (Pubitemid 40446252)
21. Patterson KC, Weissmann A, Ahmadi T, Farber HW. Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006;145:152-153. (Pubitemid 46780594)
22. Hughes AD. Increase in tone and intracellular Ca21 in rabbit isolated ear artery by platelet-derived growth factor. Br J Pharmacol 1995;114:138-142.
23. Ito A, Shimokawa H, Nakaike R, Fukai T, Sakata M, Takayanagi T, Egashira K, Takeshita A. Role of protein kinase C-mediated pathway in the pathogenesis of coronary artery spasm in a swine model. Circulation 1994;90:2425-2431. (Pubitemid 24354330)
24. Knock GA, Shaifta Y, Snetkov VA, Vowles B, Drndarski S, Ward JP, Aaronson PI. Interaction between src family kinases and Rho-kinase in agonist-induced Ca21-sensitization of rat pulmonary artery. Cardiovasc Res 2008;77:570-579. (Pubitemid 351197665)
25. Tang DD, Anfinogenova Y. Physiologic properties and regulation of the actin cytoskeleton in vascular smooth muscle. J Cardiovasc Pharmacol Ther 2008;13:130-140. (Pubitemid 351704167)
26. Neppl RL, Lubomirov LT, Momotani K, Pfitzer G, Eto M, Somlyo AV. Thromboxane A2-induced bi-directional regulation of cerebral arterial tone. J Biol Chem 2009;284:6348-6360.
27. Wilson DP, Susnjar M, Kiss E, Sutherland C, Walsh MP. Thromboxane A2-induced contraction of rat caudal arterial smooth muscle involves activation of Ca2+ entry and Ca2+ sensitization: Rho-associated kinase-mediated phosphorylation of mypt1 at thr-855, but not thr-697. Biochem J 2005;389:763-774. (Pubitemid 41121989)
28. Ghofrani HA, Morrell NW, Hoeper MM, Olschewski H, Peacock AJ, Barst RJ, Shapiro S, Golpon H, Toshner M, Grimminger F, et al. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171-1177.
29. Kerkela R, Grazette L, Yacobi R, Iliescu C, Patten R, Beahm C, Walters B, Shevtsov S, Pesant S, Clubb FJ, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006;12:908-916. (Pubitemid 44175142)
30. Deremer DL, Ustun C, Natarajan K. Nilotinib: a second-generation tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia. Clin Ther 2008;30:1956-1975.
31. Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov 2006;5:835-844. (Pubitemid 44480537)